1: McColm J, Brittain C, Suriyapperuma S, Swanson S, Tauscher-Wisniewski S, Foster J, Soon D, Jackson K. Evaluation of single and multiple doses of a novel mGlu2 agonist, a potential antipsychotic therapy, in healthy subjects. Br J Clin Pharmacol. 2017 Aug;83(8):1654-1667. doi: 10.1111/bcp.13252. Epub 2017 Mar 31. PubMed PMID: 28156011; PubMed Central PMCID: PMC5510079.
2: Felder CC, Schober DA, Tu Y, Quets A, Xiao H, Watt M, Siuda E, Nisenbaum E, Xiang C, Heinz B, Prieto L, McKinzie DL, Monn JA. Translational Pharmacology of the Metabotropic Glutamate 2 Receptor-Preferring Agonist LY2812223 in the Animal and Human Brain. J Pharmacol Exp Ther. 2017 Apr;361(1):190-197. doi: 10.1124/jpet.116.237859. Epub 2017 Jan 30. PubMed PMID: 28138041.
3: Monn JA, Prieto L, Taboada L, Hao J, Reinhard MR, Henry SS, Beadle CD, Walton L, Man T, Rudyk H, Clark B, Tupper D, Baker SR, Lamas C, Montero C, Marcos A, Blanco J, Bures M, Clawson DK, Atwell S, Lu F, Wang J, Russell M, Heinz BA, Wang X, Carter JH, Getman BG, Catlow JT, Swanson S, Johnson BG, Shaw DB, McKinzie DL. Synthesis and Pharmacological Characterization of C4-(Thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1R,2S,4R,5R,6R)-2-Amino-4-(1H-1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2, 6-dicarboxylic Acid (LY2812223), a Highly Potent, Functionally Selective mGlu2 Receptor Agonist. J Med Chem. 2015 Sep 24;58(18):7526-48. doi: 10.1021/acs.jmedchem.5b01124. PubMed PMID: 26313429.